NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Document | Date |
|---|---|
| Annual report FY2026 VAISHALI PHARMA LIMITED – ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹10,877.23 lakhs (FY 2025-26) vs ₹9,902.56 la | 2026-09-01 |
| Quarterly results · Q1 FY27 VAISHALI PHARMA LIMITED – BOARD MEETING SUMMARY 14th August, 2026 --- HEADLINE NUMBERS • Q1 FY2026-27 Results: Unaudited financial results for the | 2026-08-14 |
| Quarterly results · Q4 FY26 VAISHALI PHARMA LIMITED - DOCUMENT SUMMARY HEADLINE NUMBERS • Document Date: 30th May, 2026 • Stock Code: VAISHALI (National Stock Exchange of India | 2026-05-30 |
| Quarterly results · Q3 FY26 VAISHALI PHARMA LIMITED – BOARD MEETING OUTCOME (13 FEBRUARY 2026) HEADLINE NUMBERS • Preferential share issuance approved: Up to 61,23,000 equity s | 2026-02-13 |
| Quarterly results | 2026-02-05 |
| Quarterly results · Q2 FY26 VAISHALI PHARMA LIMITED – FINANCIAL SUMMARY As of 30 September 2025 --- HEADLINE NUMBERS • Revenue from operations (H1 FY2026): Rs 5,719.34 Lakh | | 2025-11-14 |
| Annual report FY2025 VAISHALI PHARMA LIMITED – ANNUAL REPORT FY 2024-25 SUMMARY --- HEADLINE NUMBERS • Company: Vaishali Pharma Limited, incorporated 1989, listed on NS | 2025-08-29 |
| Quarterly results | 2025-02-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vaishali Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.